The Efficacy of Duosomic® Iron over Standard Iron Formulations in IDA Management: A Randomized Controlled Comparative Clinical Study

Background: Iron deficiency anemia (IDA) is a common condition worldwide, and oral iron therapies have varied efficacy and safety profiles. This study aims to evaluate the comparative efficacy and safety of DUOSOMIC® Iron, Iron Sucrose Ester, and Ferrous Bisglycinate Chelate in correcting anemia, replenishing iron stores, and enhancing erythropoiesis. Methods: This paper shows results from three clinical studies: a randomized controlled trial study on DUOSOMIC® Iron, an Iron Sucrose Ester, and a Ferrous Bisglycinate Chelate. A total of 206 patients were involved. The primary endpoints were changes in hemoglobin levels, serum ferritin, and transferrin saturation. Results: DUOSOMIC® Iron resulted in significant improvements, including a mean hemoglobin increase of 5.92 g/dL for men and 4.59 g/dL for women. Serum ferritin increased by 92.17 µg/L, and transferrin saturation rose to 25%. Iron Sucrose Ester and Ferrous Bisglycinate Chelate showed moderate efficacy but required higher doses and longer treatment durations to achieve comparable results. Conclusion: DUOSOMIC® Iron demonstrated superior efficacy and safety, making it an effective treatment option for IDA